Literature DB >> 25305457

The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.

Qiang Zhang1, Xiao-yan Liu1, Teng Zhang2, Xin-feng Zhang1, Lin Zhao1, Fei Long1, Zhuang-kai Liu1, En-hua Wang3.   

Abstract

Cytokine-induced killer (CIK) cells represent a heterogeneous cell population, including a large majority of CD3+CD56+ cells, a relatively minor fractions of typical T cells (CD3+CD56-), and natural killer (NK) cells (CD3-CD56+). In order to elucidate the tumor killing mechanism of these three subpopulations of CIK cells, this review summarized the concordances and differences among CD3+CD56+ CIK cells, CD3-CD56+ NK cells and CD3+CD56- T cells to the following aspects: the effects of cell surface molecules, mechanisms of tumor killing, and clinical applications of these cells in immunotherapy. NK cells can be classified into CD56brightCD16- NK cells, which produce cytokines in response to monokine co-stimulation, and the CD56dimCD16+ NK cells, which contribute to lysing susceptible target. Also, the immunity of NK cells is mainly regulated by several immune-receptors, such as ACR, ICR, NCR and KIRs. T cells require TCR and co-stimulatory molecules for initiation of T cell activation. The CD3+CD56+ CIK cells co-express with T-cell marker CD3 and NK cell marker CD56 to appear the most potent cytotoxicity and high impact on adoptive cellular immunotherapy. These CIK subpopulations share some similar tumor killing mechanisms. LFA-1 not only mediates the binding of NK cells to target cells through its ligand ICAM-1 to localize actin accumulation but also acts as a co-stimulatory receptor on NK cells. LFA-1 also functions as co-stimulatory receptor for T cells to transmit intracellular signals from the TCR to LFA-1. Furthermore, cytotoxic effect of CD3+CD56+ CIK cells is blocked by antibodies directly against LFA-1 and its counter receptor, ICAM-1. Clinically, antibody-dependent cell-mediated cytotoxicity (ADCC) is shown in both NK cells and T cells for tumor killing while dendritic cells are another main regulator for the activation of three subpopulations. In summary, CD3+CD56+ CIK cells have dual-functional capability as T-cell subsets which acquire NK cells function and reserve TCR-mediated specific cytotoxicity. Meanwhile, CIK cells play important roles in tumor immunology. It paves the way to more effective immunotherapies for various tumors.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  CD3+CD56+ cells; Cytokine-induced killer (CIK) cells; Natural killer (NK) cells; T cells; Tumor immunology

Mesh:

Substances:

Year:  2014        PMID: 25305457     DOI: 10.1016/j.humimm.2014.09.021

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  10 in total

1.  Remodeling the fibrotic tumor microenvironment of desmoplastic melanoma to facilitate vaccine immunotherapy.

Authors:  Hongda Zhu; Qi Liu; Lei Miao; Sara Musetti; Meirong Huo; Leaf Huang
Journal:  Nanoscale       Date:  2020-01-28       Impact factor: 7.790

2.  Influence of autologous dendritic cells on cytokine-induced killer cell proliferation, cell phenotype and antitumor activity in vitro.

Authors:  Jingsong Cao; Cong Chen; Yuhuan Wang; Xuecheng Chen; Zeying Chen; Xiaoling Luo
Journal:  Oncol Lett       Date:  2016-07-11       Impact factor: 2.967

3.  The effects of hemocyanin on T cells cultured in vitro.

Authors:  Jiani Liu; Cong Chen; Chen Ling; Haoyun Hu; Jingsong Cao; Yongqiang Gao
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

4.  Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.

Authors:  Meirong Huo; Yan Zhao; Andrew Benson Satterlee; Yuhua Wang; Ying Xu; Leaf Huang
Journal:  J Control Release       Date:  2016-11-15       Impact factor: 9.776

5.  Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer.

Authors:  Jingyi Chen; Yusong Chen; Fenglan Feng; Cheng Chen; Haikang Zeng; Shuai Wen; Xin Xu; Jianxing He; Jin Li
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

6.  Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.

Authors:  Congqi Dai; Fengjuan Lin; Ruixuan Geng; Xiaoxiao Ge; Wenbo Tang; Jinjia Chang; Zheng Wu; Xinyang Liu; Ying Lin; Zhe Zhang; Jin Li
Journal:  Oncotarget       Date:  2016-03-01

Review 7.  Convergence of Innate and Adaptive Immunity during Human Aging.

Authors:  Branca I Pereira; Arne N Akbar
Journal:  Front Immunol       Date:  2016-11-04       Impact factor: 7.561

Review 8.  HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies.

Authors:  Xin Wang; Zhen-Wu Du; Tian-Min Xu; Xiao-Jun Wang; Wei Li; Jia-Li Gao; Jing Li; He Zhu
Journal:  Front Oncol       Date:  2021-12-24       Impact factor: 6.244

Review 9.  Harnessing the immune system in the battle against breast cancer.

Authors:  Elizabeth S Nakasone; Sara A Hurvitz; Kelly E McCann
Journal:  Drugs Context       Date:  2018-02-12

10.  Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma.

Authors:  Lin Hou; Qi Liu; Limei Shen; Yun Liu; Xueqiong Zhang; Fengqian Chen; Leaf Huang
Journal:  Theranostics       Date:  2018-06-13       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.